LEADER 03778nam  2200625Ia 450 
001 9910826674903321
005 20240418064811.0
010   $a1-281-32095-1
010   $a9786611320959
010   $a0-470-75714-0
010   $a0-470-75690-X
035   $a(CKB)1000000000551268
035   $a(EBL)351625
035   $a(OCoLC)437218842
035   $a(SSID)ssj0000262100
035   $a(PQKBManifestationID)11191789
035   $a(PQKBTitleCode)TC0000262100
035   $a(PQKBWorkID)10269054
035   $a(PQKB)10967100
035   $a(MiAaPQ)EBC351625
035   $a(Au-PeEL)EBL351625
035   $a(CaPaEBR)ebr10232834
035   $a(CaONFJC)MIL132095
035   $a(EXLCZ)991000000000551268
100   $a20010124d2002      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 00$aTreatment options in urological cancer$b[electronic resource] /$fedited by Jonathan Waxman
205   $a1st ed.
210   $aMalden, Mass. $cBlackwell Science$d2002
215   $a1 online resource (408 p.)
300   $aDescription based upon print version of record.
311   $a0-632-05589-8 
320   $aIncludes bibliographical references and index.
327   $aTREATMENT OPTIONS IN UROLOGICAL CANCER; Contents; Contributors; Preface; Part 1 Kidney Cancer; 1 The Molecular Biology of Kidney Cancer; 2 Cytokines and Angiogenesis Inhibitor Treatments; 3 Surgical Management of Metastatic Renal Cancer; Kidney Cancer: Commentary; Part 2 Bladder Cancer; 4 The Molecular Biology of Bladder Cancer; 5 Surgery for Advanced Bladder Cancer; 6 Chemotherapy and Bladder Cancer; 7 Treatment Options in Superficial (pTa/pT1/CIS) Bladder Cancer; Bladder Cancer: Commentary; Part 3 Prostate Cancer; 8 The Molecular Biology of Prostate Cancer
327   $a9 Surgical Pathology of Prostate Cancer10 Prostate Radiotherapy; 11 Prostate Cancer: Immediate vs. Deferred Treatment; 12 Hormone Therapy of Prostate Cancer; 13 Chemotherapy in Hormone Refractory Prostate Cancer; 14 Radical Prostatectomy; 15 The Case against Radical Surgery for Early Prostate Cancer; Prostate Cancer: Commentary; Part 4 Testicular Cancer; 16 Genetics of Adult Male Germ Cell Tumours; 17 Surveillance, Chemotherapy, and Radiotherapy for Stage 1 Testicular Germ Cell Tumours; 18 Chemotherapy of Testicular Cancer; 19 Salvage Chemotherapy Regimens for Relapsing Germ Cell Cancer
327   $a20 Surgery for Testicular CancerTesticular Cancer: Commentary; Part 5 Penile Cancer; 21 Viral Agents in the Development of Penile Cancer; 22 Current Concepts in the Management of Penile Cancer; Penile Cancer: Commentary; Index
330   $aCancer forms a large part of urological practice. Prostate cancer is the most significant and is the second most common cause of male cancer deaths with some 300,000 cases in the USA annually. Cancer of the bladder is also common. While treatment has been primarily surgical, recent years have seen an explosion of new drug therapies for urological cancers. All urologists, whether in training or in practice, need an up-to-date survey of the literature and key findings in this important and controversial field. This book takes each organ in turn (prostate, kidney, bladder, testis and penis) a
606   $aGenitourinary organs$xCancer$xTreatment
606   $aCancer$xTreatment
615  0$aGenitourinary organs$xCancer$xTreatment.
615  0$aCancer$xTreatment.
676   $a616.99/4606
676   $a616.9946
701   $aWaxman$b Jonathan$0883266
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910826674903321
996   $aTreatment options in urological cancer$91972950
997   $aUNINA